Syncona
London, Englandsynconaltd.com
Overview
Syncona is a FTSE250 company focused on founding, building and funding healthcare companies to deliver transformational treatments to patients in areas of high unmet need. Syncona is a leading life science investor focused on creating, building and scaling global leaders in life science. Syncona's purpose is to invest to extend and enhance human life.
Investments
| Company | Date | Stage | Lead |
|---|---|---|---|
| Beacon Therapeutics | Jan 2026 | Series C | Co-investor |
| Apini Therapeutics | Jun 2025 | Seed | Co-investor |
| Apini Therapeutics | Nov 2024 | Accelerator | Lead |
| Resolution Therapeutics | Oct 2024 | Series B | Lead |
| Beacon Therapeutics | Jul 2024 | Series B | Co-investor |
Key People
Roel Bulthuis
Managing Partner
Ben Woolven
Business Strategy And Operations Partner
Elisa Petris
Partner
Hitesh Thakrar
Partner
John Tsai
Executive Partner
Gonzalo Garcia
Principal
Alex Hamilton
Investor
Michael Kyriakides
Life Sciences Company Builder And Investor
Usman Sherani
Investor Relations Corporate Communications And Sustainability Associate
Sector & Stage Mix
Industry, funding stage, and valuation band breakdowns.